The paperExchangeCrypto WikiWikiAcademynotitiaplatform.com
Sign in
● LIVE
CAC 407 927,8▼ 1.89%S&P 5006 910,4▼ 3.70%EURO STOXX5 942▼ 2.81%BTC/USD58 608▼ 4.84%ETH/USD1 607,9▼ 7.98%EUR/USD1.10▼ 0.06%BRENT89.96▲ 0.58%GOLD3 517,9▼ 4.55%OAT 10Y4.91%▼ 2.77%VIX35.89▲ 26.20%CAC 407 927,8▼ 1.89%S&P 5006 910,4▼ 3.70%EURO STOXX5 942▼ 2.81%BTC/USD58 608▼ 4.84%ETH/USD1 607,9▼ 7.98%EUR/USD1.10▼ 0.06%BRENT89.96▲ 0.58%GOLD3 517,9▼ 4.55%OAT 10Y4.91%▼ 2.77%VIX35.89▲ 26.20%
 
Europe edition
Notitia
← Back
CompaniesBFM Business

Tax on the growth of sales of reimbursable medicines: the Constitutional Council invalidates the amounts paid by laboratories between 2014 and 2024

The Constitutional Council on Friday censored the method of calculating a tax on reimbursable medicines, which included commercial discounts granted to Health Insurance. Manufacturers have been contesting this…

BB
BFM Business
Newswire · 5 h ago
◌ Single source2 min read
✦ Explain it to me
Tax on the growth of sales of reimbursable medicines: the Constitutional Council invalidates the amounts paid by laboratories between 2014 and 2024

They had been campaigning for several weeks. The pharmaceutical companies won their case. The Constitutional Council on Friday invalidated the amounts paid by pharmaceutical companies between 2014 and 2024 as part of an annual State levy on the growth in sales of reimbursable medicines.

For eleven years, laboratories have paid a contribution on their turnover for reimbursable medicines, called the safeguard clause. But the method of calculating this tax was invalidated by the Court of Cassation in March 2025, which considered that discounts on products reimbursed by Health Insurance should be deducted from the turnover serving as the basis for the contribution paid by the laboratories. However, a provision provided for in Article 28 of the 2026 Social Security financing law validated the calculation method including discounts.

Around ten pharmaceutical companies, including Alexion Pharma France and Abbvie, then turned to the Constitutional Council to have this provision censored. In its decision published Friday, it declared "paragraph V of article 28 of the social security financing law for 2026 contrary to the Constitution". A validation law can only be justified by a compelling reason of general interest, however, the Sages have "deduced that no compelling reason of general interest justified the infringement caused by the contested provisions to the rights of litigants".

“In a particularly constrained budgetary context, pharmaceutical companies are fully aware of the sustainability issues of our health system,” responded Leem, a professional organization which represents nearly 200 pharmaceutical companies in France, or more than 75% of the reimbursable medicine market. “However, the decision of the Constitutional Council reminds us that the search for financial balance must be consistent with respect for legal security and the rights guaranteed by the Constitution,” he added in a message sent to AFP. Every year, pharmaceutical companies negotiate conventional rebates with the public authorities which are confidential.

They consider that these sums must be excluded from the turnover which serves as a basis for calculating the safeguard clause because they do not correspond to income actually received. A first standoff over the price already won A few months ago, the laboratories had already won a first standoff with the Economic Committee for Health Products (CEPS) in charge of setting the prices of medicines. The laboratories had managed to better remunerate innovation thanks to the profits generated by the end of the drug's life.

“We are asking in return for security of supply for these products, otherwise we will have to review this improvement,” CEPS warned. Drug companies have also managed to take the effects of the drug on the health system into account in the price. These are called positive externalities.

These must be justified by the company and substantiated by an "analysis validated by a technical exchange between the General Secretariat of the Committee and the services of the High Authority for Health", supplemented by "a real-life study intended to ensure verification of the expected savings, and validated by a third party independent of the company". This advantageous price is however limited in time and a “minimum discount of 10%” is applied when the patent falls, set the CEPS, to avoid slippage in public accounts, while the Social Security deficit could reach 23 billion euros at the end of 2026.

Source · BFM Business ↗

Machine-translated from French

Not cross-checked yet

Only BFM Business reports this story so far. We show it as a single source until another newsroom confirms it.

The reports
  1. BFM Business
    20 Nov, 18:00
Trust score: 78/100
Publisher BFM Business (established tier)+76
Detailed summary+2
Total78

Method: reports are grouped by the words of their headline and summary; each newsroom counts once; figures are read from the reports as published. Nothing here is written by an AI.